Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright

Acrivon Therapeutics (NASDAQ:ACRV)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Thursday, MarketBeat reports. They presently have a $22.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 216.09% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the stock. LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Monday, September 16th. JMP Securities reiterated a “market outperform” rating and issued a $17.00 price target on shares of Acrivon Therapeutics in a research report on Monday, September 16th. Piper Sandler Companies reiterated a “buy” rating and issued a $30.00 price target on shares of Acrivon Therapeutics in a research report on Friday, September 6th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $28.00 price target (up from $25.00) on shares of Acrivon Therapeutics in a research report on Monday, September 16th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.67.

Acrivon Therapeutics Stock Performance

Shares of ACRV opened at $6.96 on Thursday. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $11.90. The company has a market cap of $215.57 million, a price-to-earnings ratio of -2.58 and a beta of 0.66. The firm has a fifty day moving average of $7.78 and a 200-day moving average of $7.79.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. Analysts predict that Acrivon Therapeutics will post -2.4 EPS for the current year.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. American International Group Inc. grew its stake in Acrivon Therapeutics by 39.2% during the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock valued at $43,000 after acquiring an additional 1,695 shares in the last quarter. Rhumbline Advisers grew its stake in Acrivon Therapeutics by 48.9% during the 2nd quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock valued at $94,000 after acquiring an additional 5,320 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Acrivon Therapeutics during the 2nd quarter valued at about $58,000. XTX Topco Ltd purchased a new position in Acrivon Therapeutics during the 2nd quarter valued at about $61,000. Finally, Barclays PLC grew its stake in shares of Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after buying an additional 11,273 shares in the last quarter. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.